Premium
Efficacy of Nafamostat Mesilate as a Regional Anticoagulant in Experimental Direct Hemoperfusion and in Plasma Exchange on Humans
Author(s) -
Abe Hajime,
Tani Tohru,
Numa Kenji,
Endo Yoshihiro,
Yoshioka Toyokazu,
Kodama Masashi
Publication year - 1992
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1992.tb00295.x
Subject(s) - hemoperfusion , anticoagulant , plasma concentration , pharmacology , medicine , intensive care medicine , hemodialysis
As an anticoagulant, we compared Nafamostat mesilate (FUT) to heparin in experimental direct hemoperfusion (DHP) and studied the efficacy of FUT in clinical plasma exchange (PE). In in vitro study, FUT (5 μg/ ml) inhibited the activation of C4 more strongly than heparin (100 U/h), and larger dose of FUT (50 μ g/ml) inhibited the activation of C3. Experimental DHP with FUT on jaundiced dogs was safely performed, but not with heparin. Clinical PE with FUT was safely performed and the hemostatic condition was not aggravated either during or after PE in patients with bleeding.